Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Weighted Average): 2016-2025

Historic Shares Outstanding (Weighted Average) for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $96.4 million.

  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) rose 4.56% to $96.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.4 million, marking a year-over-year increase of 4.56%. This contributed to the annual value of $92.3 million for FY2024, which is 12.46% up from last year.
  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) amounted to $96.4 million in Q3 2025, which was up 1.94% from $94.5 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Shares Outstanding (Weighted Average) high stood at $96.4 million for Q3 2025, and its period low was $66.9 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $83.1 million (2024), whereas its average is $84.4 million.
  • Data for Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) shows a peak YoY rose of 28.92% (in 2024) over the last 5 years.
  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) (Quarterly) stood at $68.2 million in 2021, then rose by 2.85% to $70.1 million in 2022, then grew by 17.13% to $82.1 million in 2023, then rose by 12.46% to $92.3 million in 2024, then increased by 4.56% to $96.4 million in 2025.
  • Its last three reported values are $96.4 million in Q3 2025, $94.5 million for Q2 2025, and $92.5 million during Q1 2025.